Finnrick Verify Data Reveals Multi-Billion Dollar Peptide Industry Compliance Gaps
Title: Finnrick Verify Data Reveals Multi-Billion Dollar Peptide Industry Compliance Gaps Abstract: Finnrick Verify’s audit of 1,200+ peptide products reveals a 37% compliance gap in ingredient purity and labeling accuracy, exposing a $2.8B market risk. While the global peptide industry grows at 8.5% CAGR (2024–2030), only 12% of brands hold GMP or ISO 9001 certifications. Leading brands (e.g., Bachem, CPC Scientific) demonstrate >99% purity via HPLC, versus generic suppliers averaging 85%. Key compliance gaps include unverified certificates of analysis (CoA) and cold-chain logistics failures. Finnrick’s data-driven verification framework prioritizes third-party testing, batch traceability, and temperature-controlled shipping, guiding buyers toward certified, high-purity peptides for research and therapeutic use.